A kit for detecting platelet aggregation function based on CRET technology and a detection method thereof

By using a CRET-based reagent kit, which utilizes CD61 and PAC-1 antibody pairing and quantum dot labeling, direct and accurate detection of platelet aggregation function is achieved. This solves the problems of complex operation, long time consumption, and high cost in existing technologies. It is suitable for patients with low platelet counts, with a detection error of less than 5%, and the cost is only 1/5 of existing technologies, making it suitable for clinical applications in multiple scenarios.

CN122283152APending Publication Date: 2026-06-26NANJING POCLIGHT BIOTECHNOLOGY CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
NANJING POCLIGHT BIOTECHNOLOGY CO LTD
Filing Date
2026-05-28
Publication Date
2026-06-26

Smart Images

  • Figure CN122283152A_ABST
    Figure CN122283152A_ABST
Patent Text Reader

Abstract

This invention belongs to the field of bioassay technology, specifically relating to a kit and method for detecting platelet aggregation function based on CRET technology. The kit includes an anticoagulant, a platelet aggregation inducer, a donor probe, a receptor probe, a chemiluminescent substrate, a positive control, a negative control, and a buffer solution. The donor probe is an HRP-labeled CD61 antibody, and the receptor probe is an amino-modified CdTe quantum dot-labeled PAC-1 antibody or a CD62P antibody. This kit, based on CRET technology, enables rapid and accurate detection of platelet aggregation, is particularly suitable for low-platelet samples, and is low-cost and interference-resistant.
Need to check novelty before this filing date? Find Prior Art